83 results
424B3
ATXI
Avenue Therapeutics Inc
10 May 24
Prospectus supplement
4:53pm
payments made to such holder, unless such holder enters into an agreement with the U.S. Department of Treasury to collect and provide substantial
424B5
ATXI
Avenue Therapeutics Inc
10 May 24
Prospectus supplement for primary offering
4:52pm
Stockholders’ Equity Letter”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”), notifying us that we
8-K
ATXI
Avenue Therapeutics Inc
15 Mar 24
Other Events
7:15am
the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (the “Nasdaq”) notifying the Company that it was not in compliance
424B3
ATXI
Avenue Therapeutics Inc
2 Feb 24
Prospectus supplement
12:00am
, unless such holder enters into an agreement with the U.S. Department of Treasury to collect and provide substantial information regarding its U.S
8-K
sazgjyqznrzt laytj
24 Nov 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
1:19pm
8-K
EX-10.2
g2ntk6nui6rp16s0f
2 Nov 23
Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering
4:10pm
8-K
EX-99.1
aonkr8
2 Nov 23
Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering
4:10pm
8-K
EX-99.2
2nh2sdhrpj2w7 kg
2 Nov 23
Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering
4:10pm
424B4
uam2uez 4np
2 Nov 23
Prospectus supplement with pricing info
9:00am
8-K
383wy44u
28 Sep 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:25pm
8-K
7qvkzze 6b25i4it5
21 Jul 23
Other Events
4:37pm
424B3
td8wi8ah6brgr
28 Jun 23
Prospectus supplement
4:56pm